Second Regular Session Seventy-fourth General Assembly STATE OF COLORADO

ENGROSSED

This Version Includes All Amendments Adopted on Second Reading in the House of Introduction

LLS NO. 24-0313.01 Brita Darling x2241

SENATE BILL 24-047

SENATE SPONSORSHIP

Jaquez Lewis and Priola,

HOUSE SPONSORSHIP

Young and Epps, Kipp

Senate Committees

House Committees

Health & Human Services Finance Appropriations

A BILL FOR AN ACT

101 CONCERNING THE PREVENTION OF SUBSTANCE USE <u>DISORDERS</u>, AND, IN
102 CONNECTION THEREWITH, MAKING AN APPROPRIATION.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://leg.colorado.gov/.)

Opioid and Other Substance Use Disorders Study Committee. Sections 1 through 8 of the bill:

- Exempt veterinarians from complying with specific aspects of the prescription drug monitoring program (program) that are specific to prescriptions for human patients;
- Add reporting requirements for gabapentin, in addition to

- prescriptions for controlled substances in this state, to the program;
- Allow the medical director of a medical practice or hospital to appoint designees to query the program on behalf of a practitioner in the medical practice or hospital setting;
- Allow the department of health care policy and financing to access the program, consistent with federal data privacy requirements, for purposes of care coordination, utilization review, and federally required reporting relating to recipients of certain benefits; and
- Update current language in the laws relating to the program by using more modern terminology.

Sections 9 and 11 create the substance use disorder prevention gap grant program (grant program) in the department of public health and environment (department). The grant program provides grants to community-based organizations to fill gaps in funding for substance use disorder prevention services in areas of highest need, including community-oriented, children-oriented, youth-oriented, and family-oriented prevention services.

The department, in conjunction with the Colorado substance use disorders prevention collaborative (prevention collaborative), shall create a publicly available prevention services gap assessment tool to direct grant program awards to areas of highest need. After review of applications, the prevention collaborative shall make recommendations to the department, and, subject to available appropriations, the department shall award 2-year grants based on those recommendations.

The bill requires the department to administer the grant program and application process and authorizes the executive director of the department to promulgate rules as necessary to implement the grant program. The department shall begin accepting grant applications no later than December 31, 2024.

The bill requires the general assembly to appropriate to the department \$1,500,000 from the general fund to implement the grant program. The grant program repeals in 2028.

Section 10 permits a multidisciplinary and multiagency drug overdose fatality review team established for a county, a city and county, a group of counties or cities and counties, or an Indian tribe (local team) to request and receive information from certain specified persons and entities as necessary to carry out the purpose and duties of the local team. Upon written request of the chair of a local team, a person or entity shall provide the local team with information and records regarding the person whose death or near death is being reviewed by the local team.

A person or entity that receives a records request from a local team may charge the local team a reasonable fee for the service of duplicating any records requested by the local team.

-2- 047

A person or entity, including a local or state agency, that provides information or records to a local team is not subject to civil or criminal liability or any professional disciplinary action pursuant to state law as a result of providing the information or record.

Upon request of a local team, a person who is not a member of a local team may attend and participate in a meeting at which a local team reviews confidential information and considers a plan, an intervention, or other course of conduct based on that review. The bill requires each person at a local team meeting to sign a confidentiality form before reviewing information and records received by the local team. Local team meetings in which confidential information is discussed are exempt from the open meetings provisions of the "Colorado Sunshine Act of 1972".

A local team shall maintain the confidentiality of information provided to the local team as required by state and federal law, and information and records acquired or created by a local team are not subject to inspection pursuant to the "Colorado Open Records Act". Local team members and a person who presents or provides information to a local team may not be questioned in any civil or criminal proceeding or disciplinary action regarding the information presented or provided.

Section 12 requires the department of health care policy and financing to publish guidance for providers concerning reimbursement for all variations of screening, brief intervention, and referral to treatment interventions.

Section 13 requires the substance use screening, brief intervention, and referral to treatment grant program to implement:

- A statewide adolescent substance use screening, brief intervention, and referral practice that includes training and technical assistance for appropriate professionals in Colorado schools, with the purpose of identifying students who would benefit from screening, brief intervention, and potential referral to resources, including treatment; and
- A statewide substance use screening, brief intervention, and referral practice for pediatricians and professionals in pediatric settings, with the purpose of identifying adolescent patients who would benefit from screening, brief intervention, and potential referral to resources, including treatment.

Current law authorizes the center for research into substance use disorder prevention, treatment, and recovery support strategies (center) to conduct a statewide perinatal substance use data linkage project (data linkage project) that uses ongoing collection, analysis, interpretation, and dissemination of data for the planning, implementation, and evaluation of public health actions to improve outcomes for families impacted by substance use during pregnancy. **Section 14**:

• Requires the center to conduct the data linkage project;

-3-

- Requires the data linkage project to utilize data from additional state and federal programs; and
- Expands the data linkage project to examine the education of pregnant and postpartum women with substance use disorders.

Section 15 authorizes the university of Colorado school of medicine (school of medicine) to conduct a statewide opioid use disorder prevalence data linkage project (data linkage project) that uses ongoing collection, analysis, interpretation, and dissemination of data for the planning, implementation, and evaluation of public health actions to improve outcomes for individuals with opioid misuse or use disorders. The bill includes sources of data to be used in the data linkage project. The governor's office of information technology shall perform secure linkage and anonymization of the data. The school of medicine will report annually to certain committees of the general assembly on the data linkage project and its outcomes.

1 Be it enacted by the General Assembly of the State of Colorado: 2 SECTION 1. In Colorado Revised Statutes, 12-30-109, amend 3 (4)(e); and **repeal** (4)(f) as follows: 4 12-30-109. Prescriptions - limitations - definition - rules. 5 (4) As used in this section, "prescriber" means: 6 (e) A podiatrist licensed pursuant to article 290 of this title 12; OR 7 (f) A veterinarian licensed pursuant to part 1 of article 315 of this title 12; or 8 9 **SECTION 2.** In Colorado Revised Statutes, 12-280-401, amend 10 (1)(b), (1)(c), and (1)(d) as follows: 11 **12-280-401.** Legislative declaration. (1) The general assembly 12 finds, determines, and declares that: 13 (b) Prescription drug misuse occurs at times due to the deception 14 of the authorized practitioners, where patients seek controlled substances 15 for treatment and the practitioner is unaware of the patient's other medical 16 providers and treatments;

-4- 047

1	(c) Electronic monitoring of prescriptions for controlled
2	substances AND <u>GABAPENTINOIDS</u> provides a mechanism whereby
3	practitioners can discover the extent of each patient's requests for drugs
4	and whether other providers have prescribed similar substances during a
5	similar period of time; AND
6	(d) Electronic monitoring of prescriptions for controlled
7	substances AND <u>GABAPENTINOIDS</u> provides a mechanism for law
8	enforcement officials and regulatory boards to efficiently investigate
9	practitioner behavior that is potentially harmful to the public.
10	SECTION 3. In Colorado Revised Statutes, 12-280-402, add
11	(2.3) and (2.5) as follows:
12	12-280-402. Definitions. As used in this part 4, unless the context
13	otherwise requires:
14	(2.3) "Hospital" means a hospital licensed or certified
15	PURSUANT TO SECTION 25-1.5-103.
16	(2.5) "MEDICAL DIRECTOR" MEANS A MEDICAL DIRECTOR OR
17	NURSE MEDICAL DIRECTOR OF A MEDICAL PRACTICE OR HOSPITAL IN THIS
18	STATE WHO IS A "PRESCRIBER" AS DEFINED IN SECTION 12-30-111 (4).
19	SECTION 4. In Colorado Revised Statutes, 12-280-403, amend
20	(1) introductory portion, (1)(c), (2)(a), (2)(b), (2)(c), and (3) as follows:
21	12-280-403. Prescription drug use monitoring program -
22	registration required - applications - rules - appropriation - repeal.
23	(1) The board shall develop or procure a prescription controlled
24	substance PRESCRIPTION DRUG electronic program to track information
25	regarding prescriptions for controlled substances AND <u>GABAPENTINOIDS</u>
26	dispensed in Colorado, including the following information:
27	(c) The name and amount of the controlled substance AND THE

-5- 047

1 AMOUNT OF THE GABAPENTINOIDS; 2 (2) (a) Each practitioner licensed in this state who holds a current 3 registration issued by the federal drug enforcement administration, and 4 each pharmacist licensed in this state, AND EACH MEDICAL DIRECTOR shall 5 register and maintain a user account with the program. 6 (b) When registering with the program or at any time thereafter 7 AFTER REGISTRATION, a practitioner may authorize designees to access the 8 program under section 12-280-404 (3)(b) or (3)(d) on behalf of the 9 practitioner, and a pharmacist may authorize designees to access the 10 program under section 12-280-404 (3)(f), AND A MEDICAL DIRECTOR MAY 11 AUTHORIZE DESIGNEES TO ACCESS THE PROGRAM UNDER SECTION 12 12-280-404 (3)(m) if: 13 (I)(A) The authorized designee of the practitioner is employed by, 14 or is under contract with, the same professional practice as the 15 practitioner OR MEDICAL DIRECTOR; or 16 (B) The authorized designee of the pharmacist is employed by, or 17 is under contract with, the same prescription drug outlet as the 18 pharmacist; and 19 (II) The practitioner, or pharmacist, OR MEDICAL DIRECTOR takes 20 reasonable steps to ensure that the designee is sufficiently competent in 21 the use of the program; and 22 (III) The practitioner, or pharmacist, OR MEDICAL DIRECTOR 23 remains responsible for: 24 (A) Ensuring that access to the program by the practitioner's OR 25

MEDICAL DIRECTOR'S designee is limited to the purposes authorized in

section 12-280-404 $\frac{(3)(b)}{(3)(b)}$ or $\frac{(3)(d)}{(3)(b)}$, $\frac{(3)(d)}{(3)(d)}$, OR $\frac{(3)(m)}{(3)(m)}$, or that

access to the program by the pharmacist's designee is limited to the

26

27

047 -6-

1 purposes authorized in section 12-280-404 (3)(f), as the case may be, and 2 that access to the program occurs in a manner that protects the 3 confidentiality of the information obtained from the program; and 4 (B) Any negligent breach of confidentiality of information 5 obtained from the program by the practitioner's or pharmacist's designee 6 when the designee accessed the program on behalf of the A supervising 7 practitioner, or pharmacist, OR MEDICAL DIRECTOR. 8 (c) A practitioner, or pharmacist, OR MEDICAL DIRECTOR is subject 9 to penalties pursuant to section 12-280-406 for violating the requirements 10 of subsection (2)(b) of this section. 11 (3) Each practitioner and each dispensing pharmacy shall disclose 12 to a patient receiving a controlled substance OR GABAPENTINOID that his 13 or her THE PATIENT'S identifying prescription information will be entered 14 into the program database and may be accessed for limited purposes by 15 specified individuals. 16 **SECTION 5.** In Colorado Revised Statutes, 12-280-404, amend 17 (2)(c), (3)(b), (3)(c)(1), (3)(d), (3)(f), (4)(a) introductory portion, (4)(a.5), 18 and (4)(c); repeal (2)(b)(1); and add (3)(m), (3)(n), and (3)(o) as follows: 19 12-280-404. Program operation - access - rules - definitions. 20 (2) (b) The rules adopted pursuant to subsection (2)(a) of this section 21 may: 22 Identify prescription drugs and substances by using (I) 23 evidence-based practices, in addition to controlled substances, that have 24 a substantial potential for abuse and must require pharmacists and 25 prescription drug outlets to report those prescription drugs and substances 26 to the program when they are dispensed to a patient; and

(c) The board shall determine if the program should track all

27

-7- 047

prescription drugs prescribed in this state. If the board makes such determination, the board shall promulgate rules on or before June 1, 2022, to include all prescription drugs in the program. If the board determines that one or more prescription drugs should not be tracked through the program, the board shall publicly note the justification for such exclusion during the rule-making process The Program shall track all controlled substances and <u>Gabapentinoids</u> dispensed in this state. Each pharmacy shall upload all controlled substances and <u>Gabapentinoids</u> dispensed in Each pharmacy in accordance <u>With all applicable reporting requirements</u>.

- (3) The program is available for query only to the following persons or groups of persons:
- (b) Any A practitioner with the statutory authority to prescribe controlled substances PRESCRIPTIVE AUTHORITY, or an individual designated by the practitioner OR A MEDICAL DIRECTOR to act on his or her THE PRACTITIONER'S OR MEDICAL DIRECTOR'S behalf in accordance with section 12-280-403 (2)(b), to the extent the query relates to a current patient of the practitioner. The practitioner or his or her THE PRACTITIONER'S designee shall identify his or her THE PERSON'S area of health-care specialty or practice upon the initial query of the program.
- (c) (I) Any A veterinarian with statutory authority to prescribe controlled substances, to the extent the query relates to a current patient or to a client and if the veterinarian, in the exercise of professional judgment, has a reasonable basis to suspect the client has committed drug abuse A SUBSTANCE USE DISORDER or has mistreated an animal.
- (d) A practitioner OR MEDICAL DIRECTOR, or an individual designated by the practitioner OR MEDICAL DIRECTOR to act on his or her

-8-

THE PRACTITIONER'S OR MEDICAL DIRECTOR'S behalf in accordance with
section 12-280-403 (2)(b), engaged in a legitimate program to monitor a
patient's drug abuse SUBSTANCE USE DISORDER;
(f) A pharmacist, an individual designated by a pharmacist in
accordance with section 12-280-403 (2)(b) to act on his or her THE
PHARMACIST'S behalf, or a pharmacist licensed in another state, to the
extent the information requested relates specifically to a current patient
to whom the pharmacist is dispensing or considering dispensing a
controlled substance or prescription drug or a patient to whom the
pharmacist is currently providing clinical patient care services;
(m) The medical director in each director's role at a
MEDICAL PRACTICE OR HOSPITAL WITH RESPECT TO ANY CURRENT PATIENT
OF THE MEDICAL PRACTICE OR HOSPITAL UNDER THE DIRECTOR'S
OF THE MEDICAL PRACTICE OR HOSPITAL UNDER THE DIRECTOR'S SUPERVISION; AND
SUPERVISION; AND
SUPERVISION; AND (n) (I) THE EXECUTIVE DIRECTOR OF THE DEPARTMENT OF HEALTH
SUPERVISION; AND (n) (I) THE EXECUTIVE DIRECTOR OF THE DEPARTMENT OF HEALTH CARE POLICY AND FINANCING OR THE EXECUTIVE DIRECTOR'S DESIGNEE,
SUPERVISION; AND (n) (I) THE EXECUTIVE DIRECTOR OF THE DEPARTMENT OF HEALTH CARE POLICY AND FINANCING OR THE EXECUTIVE DIRECTOR'S DESIGNEE, FOR THE PURPOSES OF CARE COORDINATION, UTILIZATION REVIEW, AND
SUPERVISION; AND (n) (I) THE EXECUTIVE DIRECTOR OF THE DEPARTMENT OF HEALTH CARE POLICY AND FINANCING OR THE EXECUTIVE DIRECTOR'S DESIGNEE, FOR THE PURPOSES OF CARE COORDINATION, UTILIZATION REVIEW, AND FEDERALLY REQUIRED REPORTING PERTAINING TO RECIPIENTS OF BENEFITS
SUPERVISION; AND (n) (I) THE EXECUTIVE DIRECTOR OF THE DEPARTMENT OF HEALTH CARE POLICY AND FINANCING OR THE EXECUTIVE DIRECTOR'S DESIGNEE, FOR THE PURPOSES OF CARE COORDINATION, UTILIZATION REVIEW, AND FEDERALLY REQUIRED REPORTING PERTAINING TO RECIPIENTS OF BENEFITS UNDER THE "COLORADO MEDICAL ASSISTANCE ACT", ARTICLES 4, 5, AND
SUPERVISION; AND (n) (I) THE EXECUTIVE DIRECTOR OF THE DEPARTMENT OF HEALTH CARE POLICY AND FINANCING OR THE EXECUTIVE DIRECTOR'S DESIGNEE, FOR THE PURPOSES OF CARE COORDINATION, UTILIZATION REVIEW, AND FEDERALLY REQUIRED REPORTING PERTAINING TO RECIPIENTS OF BENEFITS UNDER THE "COLORADO MEDICAL ASSISTANCE ACT", ARTICLES 4, 5, AND 6 OF TITLE 25.5, AND ENROLLEES UNDER THE "CHILDREN'S BASIC HEALTH
<u>(n)</u> (I) The executive director of the department of health care policy and financing or the executive director's designee, for the purposes of care coordination, utilization review, and federally required reporting pertaining to recipients of benefits under the "Colorado Medical Assistance Act", articles 4, 5, and 6 of title 25.5, and enrollees under the "Children's Basic Health Plan Act", article 8 of title 25.5, as long as the department's use
<u>(n)</u> (I) The executive director of the department of health care policy and financing or the executive director's designee, for the purposes of care coordination, utilization review, and federally required reporting pertaining to recipients of benefits under the "Colorado Medical Assistance Act", articles 4, 5, and 6 of title 25.5, and enrollees under the "Children's Basic Health Plan Act", article 8 of title 25.5, as long as the department's use of the program data is consistent with the federal "Health

INFORMATION UNLESS EXEMPTED FROM THE REQUIREMENT.

27

-9- 047

1	(II) THE DEPARTMENT OF HEALTH CARE POLICY AND FINANCING
2	SHALL USE THE DATA COLLECTED PURSUANT TO SUBSECTION $\underline{(3)(n)(I)}$ OF
3	THIS SECTION TO REVIEW AND ANALYZE CURRENT RULES AND OTHER
4	POLICIES, APPROPRIATE UTILIZATION, AND SAFE PRESCRIBING PRACTICES.
5	(4) (a) Each A practitioner, EXCEPT FOR A VETERINARIAN
6	LICENSED PURSUANT TO PART 1 OF ARTICLE 315 OF THIS TITLE 12, or the
7	practitioner's designee OF A PRACTITIONER OR MEDICAL DIRECTOR shall
8	query the program prior to prescribing an opioid unless the patient
9	receiving the prescription:
10	(a.5) Each A practitioner, EXCEPT A VETERINARIAN LICENSED
11	PURSUANT TO PART 1 OF ARTICLE 315 OF THIS TITLE 12, or the
12	practitioner's designee OF A PRACTITIONER OR MEDICAL DIRECTOR shall
13	query the program before prescribing a benzodiazepine to a patient unless
14	the benzodiazepine is prescribed to treat a patient in hospice or to treat
15	epilepsy, a seizure or seizure disorder, a suspected seizure disorder,
16	spasticity, alcohol withdrawal, or a neurological condition, including a
17	posttraumatic brain injury or catatonia.
18	(c) A practitioner or the practitioner's designee OF A PRACTITIONER
19	OR OF A MEDICAL DIRECTOR complies with this subsection (4) if the
20	practitioner or THE practitioner's OR MEDICAL DIRECTOR'S designee
21	attempts to access the program before prescribing an opioid or a
22	benzodiazepine and the program is not available or is inaccessible due to
23	technical failure.
24	SECTION 6. In Colorado Revised Statutes, 12-280-407, amend
25	(2) as follows:
26	12-280-407. Prescription drug outlets - prescribers -
27	responsibilities - liability. (2) A practitioner who has, in good faith,

-10-

1	written a prescription for a controlled substance or GABAPENTINOID to a
2	patient is not liable for information submitted to the program. A
3	practitioner, THE DESIGNEE OF A PRACTITIONER OR MEDICAL DIRECTOR, or
4	prescription drug outlet who THAT has, in good faith, submitted the
5	required information to the program is not liable for participation in the
6	program.
7	SECTION 7. In Colorado Revised Statutes, 12-280-408, amend
8	(2) as follows:
9	12-280-408. Exemption - waiver. (2) A prescription drug outlet
10	that does not report controlled substance AND GABAPENTINOID data to the
11	program due to a lack of electronic automation of the outlet's business
12	may apply to the board for a waiver from the reporting requirements.
13	SECTION 8. In Colorado Revised Statutes, repeal 12-315-126
14	as follows:
15	12-315-126. Prescriptions - limitations. A veterinarian is subject
16	to the limitations on prescriptions specified in section 12-30-109.
17	
18	SECTION 9. In Colorado Revised Statutes, add part 22 to article
19	20.5 of title 25 as follows:
20	PART 22
21	LOCAL OVERDOSE FATALITY REVIEW
22	25-20.5-2201. Definitions. AS USED IN THIS PART 22, UNLESS THE
23	CONTEXT OTHERWISE REQUIRES:
24	(1) "Behavioral health entity" has the same meaning as
25	SET FORTH IN SECTION 27-50-101 (4).
26	(2) "HEALTH-CARE FACILITY" MEANS A FACILITY LICENSED OR
27	CERTIFIED BY THE DEPARTMENT PURSUANT TO SECTION 25-1.5-103.

-11- 047

1	(3) "LOCAL TEAM" MEANS A MULTIDISCIPLINARY AND
2	MULTIAGENCY DRUG OVERDOSE FATALITY REVIEW TEAM ESTABLISHED
3	FOR A COUNTY, A CITY AND COUNTY, A GROUP OF COUNTIES OR CITIES AND
4	COUNTIES, OR AN INDIAN TRIBE.
5	(4) "OVERDOSE FATALITY REVIEW" MEANS A PROCESS IN WHICH A
6	MULTIDISCIPLINARY TEAM PERFORMS A SERIES OF INDIVIDUAL OVERDOSE
7	FATALITY REVIEWS TO EFFECTIVELY IDENTIFY SYSTEM GAPS AND
8	INNOVATIVE COMMUNITY-SPECIFIC OVERDOSE PREVENTION AND
9	INTERVENTION STRATEGIES.
10	25-20.5-2202. Overdose fatality review access to information
11	- fees - disclosure - no liability for sharing records. (1) The chair of
12	A LOCAL TEAM MAY REQUEST INFORMATION FROM A PERSON, AGENCY, OR
13	ENTITY DESCRIBED IN SUBSECTION (2) OF THIS SECTION AS NECESSARY TO
14	CARRY OUT THE PURPOSES AND DUTIES OF THE LOCAL TEAM THAT ARE SET
15	FORTH IN THE ORDER, AGREEMENT, OR OTHER DOCUMENT ESTABLISHING
16	THE LOCAL TEAM. SUBJECT TO SUBSECTION (4) OF THIS SECTION, BUT
17	NOTWITHSTANDING ANY OTHER PROVISION OF STATE OR LOCAL LAW TO
18	THE CONTRARY, UPON WRITTEN REQUEST OF THE CHAIR OF A LOCAL TEAM,
19	A PERSON, AGENCY, OR ENTITY SHALL PROVIDE THE LOCAL TEAM WITH THE
20	FOLLOWING:
21	(a) If the Person, agency, or entity is a health-care
22	PROVIDER, SUBSTANCE USE DISORDER TREATMENT PROVIDER, HOSPITAL,
23	OR OTHER HEALTH-CARE FACILITY OR BEHAVIORAL HEALTH ENTITY,
24	INFORMATION AND RECORDS MAINTAINED BY THE PERSON, AGENCY, OR
25	ENTITY REGARDING THE PHYSICAL HEALTH, MENTAL HEALTH, AND
26	SUBSTANCE USE DISORDER TREATMENT FOR A PERSON WHOSE DEATH OR
27	NEAR DEATH IS BEING REVIEWED BY THE LOCAL TEAM; AND

-12- 047

1	(b) IF THE AGENCY OR ENTITY IS A STATE OR LOCAL GOVERNMENT
2	AGENCY OR ENTITY THAT PROVIDED SERVICES TO A PERSON WHOSE DEATH
3	OR NEAR DEATH IS BEING REVIEWED BY THE LOCAL TEAM OR PROVIDED
4	SERVICES TO THE FAMILY OF THE PERSON, INFORMATION AND RECORDS
5	MAINTAINED BY THE AGENCY OR ENTITY ABOUT THE PERSON, INCLUDING
6	DEATH INVESTIGATIVE INFORMATION, MEDICAL EXAMINER INVESTIGATIVE
7	INFORMATION, LAW ENFORCEMENT INVESTIGATIVE INFORMATION,
8	EMERGENCY MEDICAL SERVICES REPORTS, FIRE DEPARTMENT RECORDS,
9	PROSECUTORIAL RECORDS, PAROLE AND PROBATION INFORMATION AND
10	RECORDS, COURT RECORDS, SCHOOL RECORDS, AND INFORMATION AND
11	RECORDS OF A DEPARTMENT OF HUMAN OR SOCIAL SERVICES, INCLUDING
12	THE LOCAL HUMAN SERVICES AND PUBLIC HEALTH AGENCIES.
13	(2) The following persons, agencies, or entities shall
14	COMPLY WITH A RECORDS REQUEST BY THE CHAIR OF A LOCAL TEAM MADE
15	PURSUANT TO SUBSECTION (1) OF THIS SECTION:
16	(a) A CORONER OR MEDICAL EXAMINER;
17	(b) A FIRE DEPARTMENT;
18	(c) A HEALTH-CARE FACILITY;
19	(d) A HOSPITAL;
20	(e) A STATE OR LOCAL LAW ENFORCEMENT AGENCY;
21	(f) A STATE OR LOCAL GOVERNMENTAL AGENCY, INCLUDING THE
22	DEPARTMENT OF HUMAN SERVICES, INCLUDING THE BEHAVIORAL HEALTH
23	ADMINISTRATION; THE DEPARTMENT OF PUBLIC HEALTH AND
24	ENVIRONMENT, SO LONG AS THE DEPARTMENT OF PUBLIC HEALTH AND
25	ENVIRONMENT CREATED OR HOLDS THE RECORDS AND THE RELEASE DOES
26	NOT VIOLATE ANY AGREEMENT NOT TO RELEASE THE RECORDS; THE
27	DEPARTMENT OF LAW; THE OFFICE OF STATE PUBLIC DEFENDER; THE

-13-

1	DEPARTMENT OF CORRECTIONS; AND THE STATE BOARD OF PAROLE;
2	(g) A BEHAVIORAL HEALTH ENTITY;
3	(h) A HEALTH-CARE PROVIDER;
4	(i) A SUBSTANCE USE DISORDER TREATMENT PROVIDER;
5	(j) A SCHOOL, INCLUDING A PUBLIC OR PRIVATE ELEMENTARY,
6	MIDDLE, JUNIOR HIGH, OR HIGH SCHOOL, OR A PUBLIC OR PRIVATE
7	INSTITUTION OF POSTSECONDARY EDUCATION DESCRIBED IN TITLE 23,
8	INCLUDING THE AURARIA HIGHER EDUCATION CENTER CREATED IN
9	ARTICLE 70 OF TITLE 23;
10	(k) A SOCIAL SERVICES PROVIDER;
11	_
12	(1) GROUND OR AIR AMBULANCE SERVICE AGENCIES; AND
13	(m) Any other person or entity that is in possession of
14	RECORDS THAT ARE, AS DETERMINED BY THE LOCAL TEAM, PERTINENT TO
15	THE LOCAL TEAM'S INVESTIGATION OF AN OVERDOSE FATALITY.
16	(3) (a) A PERSON, AGENCY, OR ENTITY SHALL PROVIDE REQUESTED
17	INFORMATION TO THE LOCAL TEAM WITHIN FIVE BUSINESS DAYS AFTER
18	RECEIPT OF THE WRITTEN REQUEST, EXCLUDING WEEKENDS AND
19	HOLIDAYS, UNLESS AN EXTENSION IS GRANTED BY THE CHAIR OF THE
20	LOCAL TEAM. WRITTEN REQUESTS MAY INCLUDE A REQUEST SUBMITTED
21	VIA E-MAIL OR FACSIMILE TRANSMISSION.
22	(b) A PERSON, AGENCY, OR ENTITY THAT RECEIVES A RECORDS
23	REQUEST FROM A LOCAL TEAM PURSUANT TO THIS SECTION MAY CHARGE
24	THE LOCAL TEAM A REASONABLE FEE FOR THE SERVICE OF DUPLICATING
25	ANY RECORDS REQUESTED BY THE LOCAL TEAM.
26	(4) The disclosure or redisclosure, in accordance with
27	THIS SECTION OF A MEDICAL DECORD DEVELOPED IN CONNECTION WITH

-14- 047

1	THE PROVISION OF SUBSTANCE USE TREATMENT SERVICES, WITHOUT THE
2	AUTHORIZATION OF A PERSON IN INTEREST, IS SUBJECT TO ANY
3	LIMITATIONS THAT EXIST PURSUANT TO APPLICABLE STATE OR FEDERAL
4	LAW, INCLUDING A STATE LAW LISTED IN SECTION 25-1-1202, 42 U.S.C.
5	SEC. 290dd-2, AND 42 CFR 2.
6	(5) NOTWITHSTANDING ANY LAW TO THE CONTRARY, THE LOCAL
7	TEAM DOES NOT NEED AN ADMINISTRATIVE SUBPOENA OR OTHER FORM OF
8	LEGAL COMPULSION TO RECEIVE REQUESTED RECORDS.
9	(6) THE CHAIR OF A LOCAL TEAM, OR THE CHAIR'S DESIGNEE, MAY
10	REQUEST A PERSON WHOSE OVERDOSE IS UNDER REVIEW OR, IF DECEASED,
11	THE PERSON'S NEXT OF KIN TO SIGN A CONSENT FORM FOR THE RELEASE OF
12	CONFIDENTIAL INFORMATION.
13	(7) SO LONG AS EACH INDIVIDUAL PRESENT AT A LOCAL TEAM
14	MEETING HAS SIGNED THE CONFIDENTIALITY FORM DESCRIBED IN SECTION
15	25- 20.5 - 2203 , any information received by the chair of the local
16	TEAM IN RESPONSE TO A REQUEST UNDER THIS SECTION MAY BE SHARED
17	AT A LOCAL TEAM MEETING WITH LOCAL TEAM MEMBERS AND ANY
18	NONMEMBER ATTENDEES.
19	(8) A PERSON, AGENCY, OR ENTITY THAT PROVIDES INFORMATION
20	OR RECORDS TO A LOCAL TEAM PURSUANT TO THIS PART 22IS NOT SUBJECT
21	TO CIVIL OR CRIMINAL LIABILITY OR ANY PROFESSIONAL DISCIPLINARY
22	ACTION PURSUANT TO STATE LAW AS A RESULT OF PROVIDING THE
23	INFORMATION OR RECORD.
24	(9) A MEMBER OF THE LOCAL TEAM MAY CONTACT, INTERVIEW, OR
25	OBTAIN INFORMATION BY REQUEST FROM A FAMILY MEMBER OR FRIEND OF
26	A PERSON WHOSE DEATH IS BEING REVIEWED BY THE LOCAL TEAM.
27	25-20.5-2203. Confidentiality - closed meetings - records not

-15- 047

1	open to inspection - civil liability. (1) LOCAL TEAM MEETINGS IN WHICH
2	CONFIDENTIAL INFORMATION IS DISCUSSED ARE EXEMPT FROM THE OPEN
3	MEETINGS PROVISIONS OF THE "COLORADO SUNSHINE ACT OF 1972", PART
4	4 OF ARTICLE 6 OF TITLE 24, AND MUST BE CLOSED TO THE PUBLIC.
5	(2) (a) Upon request of a local team, a person who is not a
6	MEMBER OF A LOCAL TEAM MAY ATTEND AND PARTICIPATE IN A MEETING
7	AT WHICH A LOCAL TEAM REVIEWS CONFIDENTIAL INFORMATION AND
8	CONSIDERS A PLAN, AN INTERVENTION, OR OTHER COURSE OF CONDUCT
9	BASED ON THAT REVIEW.
10	(b) A LOCAL TEAM MEMBER AND ANY NONMEMBER IN
11	ATTENDANCE AT A LOCAL TEAM MEETING SHALL SIGN A CONFIDENTIALITY
12	FORM AND REVIEW THE PURPOSE AND GOAL OF THE LOCAL TEAM BEFORE
13	THE PERSON MAY PARTICIPATE IN THE REVIEW OF CONFIDENTIAL
14	INFORMATION. THE CONFIDENTIALITY FORM MUST SET OUT THE
15	REQUIREMENTS FOR MAINTAINING THE CONFIDENTIALITY OF ANY
16	INFORMATION DISCLOSED DURING THE MEETING AND ANY PENALTIES
17	ASSOCIATED WITH FAILURE TO MAINTAIN CONFIDENTIALITY.
18	(3) INFORMATION AND RECORDS ACQUIRED BY A LOCAL TEAM ARE
19	CONFIDENTIAL AND ARE NOT SUBJECT TO SUBPOENA, DISCOVERY, OR
20	INTRODUCTION INTO EVIDENCE IN A CIVIL OR CRIMINAL PROCEEDING OR
21	DISCIPLINARY ACTION. INFORMATION AND RECORDS THAT ARE OTHERWISE
22	AVAILABLE FROM OTHER SOURCES ARE NOT IMMUNE FROM SUBPOENA,
23	DISCOVERY, OR INTRODUCTION INTO EVIDENCE THROUGH THOSE SOURCES
24	SOLELY BECAUSE THE INFORMATION OR RECORD WAS PRESENTED TO OR
25	REVIEWED BY A LOCAL TEAM.
26	(4) Information and records acquired or created by A
27	LOCAL TEAM ARE NOT SUBJECT TO INSPECTION PURSUANT TO THE

-16- 047

1	"COLORADO OPEN RECORDS ACT", PART 2 OF ARTICLE 72 OF TITLE 24.
2	(5) SUBSTANCE USE DISORDER TREATMENT RECORDS REQUESTED
3	OR PROVIDED TO THE LOCAL TEAM ARE SUBJECT TO ANY ADDITIONAL
4	LIMITATIONS ON REDISCLOSURE OF A MEDICAL RECORD DEVELOPED IN
5	CONNECTION WITH THE PROVISIONS OF SUBSTANCE USE DISORDER
6	TREATMENT SERVICES PURSUANT TO APPLICABLE STATE OR FEDERAL LAW,
7	INCLUDING A STATE LAW LISTED IN SECTION 25-1-1202, 42 U.S.C. SEC.
8	290dd-2, AND 42 CFR 2.
9	(6) LOCAL TEAM MEMBERS AND A PERSON WHO PRESENTS OR
10	PROVIDES INFORMATION TO A LOCAL TEAM MAY NOT BE QUESTIONED IN
11	ANY CIVIL OR CRIMINAL PROCEEDING OR DISCIPLINARY ACTION
12	REGARDING THE INFORMATION PRESENTED OR PROVIDED. THIS
13	SUBSECTION (6) DOES NOT PREVENT A PERSON FROM TESTIFYING
14	REGARDING INFORMATION OBTAINED INDEPENDENTLY OF THE LOCAL
15	TEAM OR TESTIFYING AS TO PUBLIC INFORMATION.
16	(7) A LOCAL TEAM AND ANY NONMEMBER PARTICIPATING IN AN
17	OVERDOSE FATALITY REVIEW SHALL MAINTAIN THE CONFIDENTIALITY OF
18	INFORMATION PROVIDED TO THE LOCAL TEAM AS REQUIRED BY STATE AND
19	FEDERAL LAW. A MEMBER OF A LOCAL TEAM OR A PARTICIPATING
20	NONMEMBER WHO SHARES CONFIDENTIAL INFORMATION IN VIOLATION OF

THIS SECTION IS IMMUNE FROM CIVIL AND CRIMINAL LIABILITY IF THE PERSON ACTED IN GOOD FAITH COMPLIANCE WITH THE PROVISIONS OF THIS PART 22.

21

22

23

24

25

26

27

- (8) A PERSON WHO KNOWINGLY VIOLATES THE CONFIDENTIALITY PROVISIONS OF THIS PART 22 IS SUBJECT TO A CIVIL PENALTY OF UP TO ONE THOUSAND DOLLARS.
 - (9) This section does not prohibit a local team from

-17-047

1	REQUESTING THE ATTENDANCE AT A TEAM MEETING OF A PERSON WHO
2	HAS INFORMATION RELEVANT TO THE TEAM'S EXERCISE OF ITS PURPOSE
3	AND DUTIES.
4	25-20.5-2204. Prohibition against any law enforcement use.
5	NOTWITHSTANDING ANY PROVISION OF LAW TO THE CONTRARY, LAW
6	ENFORCEMENT SHALL NOT USE INFORMATION FROM ANY OVERDOSE
7	FATALITY REVIEW FOR ANY LAW ENFORCEMENT PURPOSE, INCLUDING
8	SURVEILLANCE, INCREASED LAW ENFORCEMENT PRESENCE, WELFARE
9	CHECKS, WARRANT CHECKS, OR CRIMINAL INVESTIGATIONS.
10	
11	SECTION <u>10.</u> In Colorado Revised Statutes, add 25.5-4-431 as
12	follows:
13	25.5-4-431. Reimbursement guidance for screening, brief
14	intervention, and referral to treatment. The STATE DEPARTMENT SHALL
15	PUBLISH GUIDANCE FOR PROVIDERS CONCERNING REIMBURSEMENT FOR
16	ALL VARIATIONS OF SCREENING, BRIEF INTERVENTION, AND REFERRAL TO
17	TREATMENT INTERVENTIONS.
18	SECTION 11. In Colorado Revised Statutes, 25.5-5-208, amend
19	(1) introductory portion; and add (1)(a.3) and (1)(a.5) as follows:
20	25.5-5-208. Additional services - training - grants - screening,
21	brief intervention, and referral. (1) On or after July 1, 2018, the state
22	department shall grant, through a competitive grant program, one million
23	five hundred thousand dollars to one or more organizations to operate a
24	substance abuse USE screening, brief intervention, and referral to
25	treatment practice. The grant program must require:
26	(a.3) Implementation of a statewide adolescent substance
27	USE SCREENING, BRIEF INTERVENTION, AND REFERRAL PRACTICE THAT

-18- 047

1	INCLUDES TRAINING AND TECHNICAL ASSISTANCE FOR APPROPRIATE
2	PROFESSIONALS IN COLORADO SCHOOLS, WITH THE PURPOSE OF
3	IDENTIFYING STUDENTS WHO WOULD BENEFIT FROM SCREENING, BRIEF
4	INTERVENTION, AND POTENTIAL REFERRAL TO RESOURCES, INCLUDING
5	TREATMENT;
6	(a.5) IMPLEMENTATION OF A STATEWIDE SUBSTANCE USE
7	SCREENING, BRIEF INTERVENTION, AND REFERRAL PRACTICE THAT
8	INCLUDES TRAINING AND TECHNICAL ASSISTANCE FOR PEDIATRICIANS AND
9	PROFESSIONALS IN PEDIATRIC SETTINGS, WITH THE PURPOSE OF
10	IDENTIFYING ADOLESCENT PATIENTS WHO WOULD BENEFIT FROM
11	SCREENING, BRIEF INTERVENTION, AND POTENTIAL REFERRAL TO
12	RESOURCES, INCLUDING TREATMENT;
13	SECTION 12. In Colorado Revised Statutes, 27-80-121, amend
14	(1) and (3) as follows:
1415	(1) and (3) as follows: 27-80-121. Perinatal substance use data linkage project -
15	27-80-121. Perinatal substance use data linkage project -
15 16	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention,
15 16 17	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for
15 16 17 18	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for research into substance use disorder prevention, treatment, and recovery
15 16 17 18 19	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for research into substance use disorder prevention, treatment, and recovery support strategies established in section 27-80-118, referred to in this
15 16 17 18 19 20	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for research into substance use disorder prevention, treatment, and recovery support strategies established in section 27-80-118, referred to in this section as the "center", in partnership with an institution of higher
15 16 17 18 19 20 21	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for research into substance use disorder prevention, treatment, and recovery support strategies established in section 27-80-118, referred to in this section as the "center", in partnership with an institution of higher education and the state substance abuse trend and response task force
15 16 17 18 19 20 21 22	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for research into substance use disorder prevention, treatment, and recovery support strategies established in section 27-80-118, referred to in this section as the "center", in partnership with an institution of higher education and the state substance abuse trend and response task force established in section 18-18.5-103, may SHALL conduct a statewide
15 16 17 18 19 20 21 22 23	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for research into substance use disorder prevention, treatment, and recovery support strategies established in section 27-80-118, referred to in this section as the "center", in partnership with an institution of higher education and the state substance abuse trend and response task force established in section 18-18.5-103, may SHALL conduct a statewide perinatal substance use data linkage project that uses ongoing collection,
15 16 17 18 19 20 21 22 23 24	27-80-121. Perinatal substance use data linkage project - center for research into substance use disorder prevention, treatment, and recovery support strategies - report. (1) The center for research into substance use disorder prevention, treatment, and recovery support strategies established in section 27-80-118, referred to in this section as the "center", in partnership with an institution of higher education and the state substance abuse trend and response task force established in section 18-18.5-103, may SHALL conduct a statewide perinatal substance use data linkage project that uses ongoing collection, analysis, interpretation, and dissemination of data for the planning,

-19- 047

1	ESTABLISHED IN articles 4 to 6 of title 25.5; the electronic prescription
2	drug monitoring program created in part 4 of article 280 of title 12; the
3	Colorado TRAILS system, as defined in section 16-20.5-102 (10); the
4	Colorado immunization information system created pursuant to section
5	25-4-2401, et seq. PART 24 OF ARTICLE 4 OF TITLE 25; the Colorado child
6	care assistance program created in part 1 of article 4 of title 26.5; the
7	BHA; THE EARLY INTERVENTION PROGRAM FOR INFANTS AND TODDLERS
8	UNDER PART C OF THE FEDERAL "INDIVIDUALS WITH DISABILITIES
9	EDUCATION ACT", 20 U.S.C. SEC. 1400 ET SEQ.; THE COLORADO
10	DEPARTMENT OF EDUCATION; OTHER DATA SOURCES RELATED TO
11	MATERNAL HEALTH, AS COLLECTED BY THE COLORADO DEPARTMENT OF
12	PUBLIC HEALTH AND ENVIRONMENT; THE COLORADO ALL-PAYER HEALTH
13	CLAIMS DATABASE DESCRIBED IN SECTION 25.5-1-204; FAMILY
14	EXPERIENCES AND PROVIDER PERSPECTIVES, WHEN NECESSARY; and birth
15	and death records to examine the following:
16	(a) Health-care mortality utilization by pregnant and postpartum
17	women with substance use disorders and their infants compared to the
18	general population;
19	(b) Human service, EDUCATION, public health program utilization,
20	and substance use treatment by pregnant and postpartum women with
21	substance use disorders and their infants COMPARED TO THE GENERAL
22	POPULATION;
23	(c) Health-care, human service, EDUCATION, and public health
24	program outcomes, INCLUDING MORBIDITY AND MORTALITY OUTCOMES,
25	among pregnant and postpartum women with substance use disorders and
26	their infants COMPARED TO THE GENERAL POPULATION; and
27	(d) Costs associated with health-care, human service, EDUCATION,

-20- 047

and public health program provisions for pregnant and postpartum women with substance use disorders and their infants COMPARED TO THE GENERAL POPULATION.

(3) The data linkage project may conduct ongoing research related to the incidence of perinatal substance exposure or related infant and family health, EDUCATION, and human service outcomes based on the standards specified in sections 19-1-103 (1)(a)(VII) and 19-3-102 (1)(g) for determining child abuse or neglect or whether a child is neglected or dependent.

SECTION 13. Appropriation. (1) For the 2024-25 state fiscal year, \$75,000 is appropriated to the department of health care policy and financing for use by the executive director's office. This appropriation is from the general fund. To implement this act, the office may use this appropriation for general professional services and special projects.

(2) For the 2024-25 state fiscal year, the general assembly anticipates that the department of health care policy and financing will receive \$75,000 in federal funds to implement this act, which amount is subject to the "(I)" notation as defined in the annual general appropriation act for the same fiscal year. The appropriation in subsection (1) of this section is based on the assumption that the department will receive this amount of federal funds to be used for general professional services and special projects.

(3) For the 2024-25 state fiscal year, \$250,000 is appropriated to the department of higher education for use by the Colorado commission on higher education and higher education special purpose programs. This appropriation is from the general fund. To implement this act, the division

-21- 047

1	may use this appropriation for the center for substance use disorder.
2	prevention, treatment, and recovery support strategies at the university of
3	Colorado health sciences center.
4	SECTION 14. Safety clause. The general assembly finds,
5	determines, and declares that this act is necessary for the immediate
5	preservation of the public peace, health, or safety or for appropriations for
7	the support and maintenance of the departments of the state and state
3	institutions.

-22- 047